On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study evaluating the combination of Talvey (talquetamab) and Tecvayli (teclistamab) in patients with relapsed or refractory multiple myeloma.
At data cutoff, 44 patients had been treated with the recommended phase 2 regimen (RP2R) of 0.8 mg/kg of Talvey in combination with 3 mg/kg of Tecvayli every other week.
The overall response rate (ORR) was 79.5%, with a complete response or better (CR+) rate of 52.3%, an 18-month duration of response (DOR) of 85.9%, and an 18-month progression-free survival (PFS) rate of 69.8% with a median follow-up of 18.2 ...
